Stemline Therapeutics Announces Positive Data Presentations on SL-701 and SL-801 at ASCO
June 05, 2018 07:00 ET
|
Stemline Therapeutics, Inc.
NEW YORK, June 05, 2018 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq:STML), a clinical-stage biopharmaceutical company developing novel oncology therapeutics, announced today that...
Stemline Therapeutics Announces Three SL-401 Clinical Presentations, Including an Oral Presentation, at the Upcoming EHA Congress
May 18, 2018 07:00 ET
|
Stemline Therapeutics, Inc.
NEW YORK, May 18, 2018 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq:STML), a clinical-stage biopharmaceutical company developing novel oncology therapeutics, announced today that SL-401...
Stemline Therapeutics Announces Presentation of SL-801 and SL-701 Clinical Data at the Upcoming ASCO Annual Meeting
May 17, 2018 07:00 ET
|
Stemline Therapeutics, Inc.
NEW YORK, May 17, 2018 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq:STML), a clinical-stage biopharmaceutical company developing novel oncology therapeutics, announced today that clinical...
Stemline Therapeutics Reports First Quarter 2018 Financial Results
May 09, 2018 16:00 ET
|
Stemline Therapeutics, Inc.
NEW YORK, May 09, 2018 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq:STML), a clinical-stage biopharmaceutical company developing novel oncology therapeutics, announced today financial...
Stemline Therapeutics Announces Clinical Presentations of SL-801 and SL-701 at the Upcoming ASCO Annual Meeting
April 26, 2018 07:00 ET
|
Stemline Therapeutics, Inc.
NEW YORK, April 26, 2018 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq:STML), a clinical-stage biopharmaceutical company developing novel oncology therapeutics, announced today that...
Stemline Therapeutics Expands Board of Directors; Further Enhances Commercial Expertise with Appointment of Darren Cline
April 16, 2018 07:00 ET
|
Stemline Therapeutics, Inc.
NEW YORK, April 16, 2018 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq:STML), a clinical-stage biopharmaceutical company developing novel oncology therapeutics, today announced expansion...
Stemline Therapeutics Announces Start of Rolling BLA Submission for SL-401
April 05, 2018 07:00 ET
|
Stemline Therapeutics, Inc.
NEW YORK, April 05, 2018 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq:STML), a clinical-stage biopharmaceutical company developing novel oncology therapeutics, announced today that it has...
Stemline Therapeutics to Present at the Oppenheimer 28th Annual Healthcare Conference
March 19, 2018 07:30 ET
|
Stemline Therapeutics, Inc.
NEW YORK, March 19, 2018 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq:STML), a clinical-stage biopharmaceutical company developing novel oncology therapeutics, announced today that Ivan...
Stemline Therapeutics Reports Fourth Quarter 2017 Financial Results
March 16, 2018 07:30 ET
|
Stemline Therapeutics, Inc.
NEW YORK, March 16, 2018 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq:STML), a clinical-stage biopharmaceutical company developing novel oncology therapeutics, announced...
Stemline Therapeutics to Present at Upcoming Investor Conferences
March 08, 2018 07:30 ET
|
Stemline Therapeutics, Inc.
NEW YORK, March 08, 2018 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq:STML), a clinical-stage biopharmaceutical company developing novel therapeutics for difficult to treat cancers,...